Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma
Inhibrx Reports First Quarter 2026 Financial Results
Inhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer Study
Inhibrx Biosciences' INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study
Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy
Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC
INBX Stock Up on Upbeat Clinical Update From Colorectal Cancer Study
Inhibrx: Spinoff Rumors Send Shares Soaring - Stunning Bull Run Can Continue
Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges
Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say
Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
Inhibrx Biosciences, Inc. (NASDAQ:INBX) Receives $150.00 Consensus Target Price from Analysts
SG Americas Securities LLC Invests $1.27 Million in Inhibrx Biosciences, Inc. $INBX
Contrasting CollPlant Biotechnologies (NASDAQ:CLGN) and Inhibrx Biosciences (NASDAQ:INBX)
Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results
7,388 Shares in Inhibrx Biosciences, Inc. $INBX Acquired by Dynamic Technology Lab Private Ltd
Inhibrx Announces Participation in Upcoming Scientific Conference
Inhibrx Biosciences, Inc. $INBX Shares Sold by Credit Industriel ET Commercial
Inhibrx: Ozekibart Beyond Chondrosarcoma, With Other Targeted Indications, Too
Why Inhibrx's Recent Strength May Not Be Built to Last
Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program
Inhibrx Biosciences (NASDAQ:INBX) Reaches New 52-Week High – Here’s Why
Stock Traders Buy High Volume of Inhibrx Biosciences Call Options (NASDAQ:INBX)
Inhibrx Reports Third Quarter 2025 Financial Results
Inhibrx Announces Participation in Upcoming Scientific Conferences
Ethic Inc. Purchases New Shares in Inhibrx Biosciences, Inc. $INBX
Inhibrx: Positive Ozekibart Data For Bone Cancer Leads To Q2 2026 BLA Filing
Inhibrx shares surge after bone cancer drug slows disease progression in trial
Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts
Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts
Inhibrx Reports Second Quarter 2025 Financial Results
Inhibrx Reports First Quarter 2025 Financial Results
Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President
Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer
Inhibrx Biosciences Announces Loan Agreement with Oxford Finance
Inhibrx Biosciences Reports Third Quarter 2024 Financial Results
Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform
Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation
Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi
Top 4 Health Care Stocks That Are Preparing To Pump This Month - Inhibrx Biosciences (NASDAQ:INBX)
Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi
Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off
INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX
Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger
Inhibrx, Inc. (INBX) Reports Q4 Loss, Tops Revenue Estimates
Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results
INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX